Article
Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
Atherosclerosis - 1 Aug 2017
Bea Ana M, Perez-Calahorra Sofia, Marco-Benedi Victoria, Lamiquiz-Moneo Itziar, Jarauta Estibaliz, Mateo-Gallego Rocio, Civeira Fernando
Abstract excerpt
BACKGROUND AND AIMS: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown. METHODS: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year. RESULTS: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.